Advanced search

Vol 58, No 2 (2020)
Original paper
Published online: 2020-06-30

open access

View PDF Download PDF file
Page views 1585
Article views/downloads 913
Get Citation

Connect on Social Media

Connect on Social Media

Downregulation of Polo-like kinase-1 (PLK-1) expression is associated with poor clinical outcome in uveal melanoma patients

Tomasz Berus1, Anna Markiewicz2, Katarzyna Kobylinska3, Przemyslaw Biecek3, Jolanta Orlowska-Heitzman4, Bozena Romanowska-Dixon2, Piotr Donizy5
DOI: 10.5603/FHC.a2020.0017
Pubmed: 32602935
Folia Histochem Cytobiol 2020;58(2):108-116.

Abstract

Introduction. Uveal melanoma (UM) is the most common primary eye tumour in adults. Distant metastases are seen in 50% of cases regardless of treatment, which contributes to high mortality rates. Polo-like kinase-1 (PLK-1) is a protein regulator of mitotic entry and cytokinesis. Increased PLK-1 expression has been shown in different tumours, which makes its inhibition a potential treatment target. To date, no study has been published to discuss the prognostic role of PLK-1 expression in patients with uveal melanoma. Material and methods. We assessed by immunohistochemistry PLK-1 expression in uveal melanoma cells collected in 158 patients treated by primary enucleation. We determined the correlation between PLK-1 levels evaluated by the immunoreactivity scale (IRS) method and detailed clinical as well as histological parameters. Additionally, we determined the association between PLK-1 expression levels and long-term prognosis. Results. Elevated PLK-1 expression in tumour cells, defined as IRS > 2, was observed in 70% (111/158) of cases, whereas low expression or no expression was seen in the remaining 30% (47/158) of patients. There was a significant correlation between low PLK-1 expression and a higher clinical tumour stage (pT, p = 0.04) as well as a higher AJCC prognostic stage group (p = 0.037). We observed an inverse correlation between PLK-1 expression and tumour cell pigment content (p = 0.0019). There was no correlation between PLK-1 expression and other histological parameters such as mitotic rate or histological subtype. The Kaplan-Meier’s analysis demonstrated that low PLK-1 expression was associated with significantly reduced overall survival (p = 0.0058). A similar trend, albeit not significant, was observed for disease-free survival (p = 0.088). Conclusions. Downregulated PLK-1 expression is a negative prognostic factor in uveal melanoma. It warrants further, multicentre research on prognostic role of PLK-1 expression and possibility of PLK-1 inhibition in uveal melanoma.

Keywords: uveal melanomapolo-like kinase-1prognostic factorIHC

Article available in PDF format

View PDF Download PDF file

References

  1. Singh AD, Turell ME, Topham AK. Uveal melanoma: trends in incidence, treatment, and survival. Ophthalmology. 2011; 118(9): 1881–1885.
    CrossRefPubMed
  2. Berus T, Halon A, Markiewicz A, et al. Clinical, Histopathological and Cytogenetic Prognosticators in Uveal Melanoma - A Comprehensive Review. Anticancer Res. 2017; 37(12): 6541–6549.
    CrossRefPubMed
  3. Rantala ES, Hernberg M, Kivelä TT. Overall survival after treatment for metastatic uveal melanoma: a systematic review and meta-analysis. Melanoma Res. 2019; 29(6): 561–568.
    CrossRefPubMed
  4. Elia AEH, Rellos P, Haire LF, et al. The molecular basis for phosphodependent substrate targeting and regulation of Plks by the Polo-box domain. Cell. 2003; 115(1): 83–95.
    CrossRefPubMed
  5. Archambault V, Lépine G, Kachaner D. Understanding the Polo Kinase machine. Oncogene. 2015; 34(37): 4799–4807.
    CrossRefPubMed
  6. Combes G, Alharbi I, Braga LG, et al. Playing polo during mitosis: PLK1 takes the lead. Oncogene. 2017; 36(34): 4819–4827.
    CrossRefPubMed
  7. Petronczki M, Lénárt P, Peters JM. Polo on the Rise-from Mitotic Entry to Cytokinesis with Plk1. Dev Cell. 2008; 14(5): 646–659.
    CrossRefPubMed
  8. Lénárt P, Petronczki M, Steegmaier M, et al. The small-molecule inhibitor BI 2536 reveals novel insights into mitotic roles of polo-like kinase 1. Curr Biol. 2007; 17(4): 304–315.
    CrossRefPubMed
  9. Barr FA, Silljé HHW, Nigg EA. Polo-like kinases and the orchestration of cell division. Nat Rev Mol Cell Biol. 2004; 5(6): 429–440.
    CrossRefPubMed
  10. Liu XS, Song B, Liu X. The substrates of Plk1, beyond the functions in mitosis. Protein Cell. 2010; 1(11): 999–1010.
    CrossRefPubMed
  11. Wolf G, Hildenbrand R, Schwar C, et al. Polo-like kinase: a novel marker of proliferation: Correlation with estrogen-receptor expression in human breast cancer. Pathology - Research and Practice. 2000; 196(11): 753–759.
    CrossRef
  12. Donizy P, Halon A, Surowiak P, et al. Augmented expression of Polo-like kinase 1 is a strong predictor of shorter cancer-specific overall survival in early stage breast cancer at 15-year follow-up. Oncol Lett. 2016; 12(3): 1667–1674.
    CrossRefPubMed
  13. Tokumitsu Y, Mori M, Tanaka S, et al. Prognostic significance of polo-like kinase expression in esophageal carcinoma. Int J Oncol. 1999; 15(4): 687–692.
    CrossRefPubMed
  14. Wolf G, Elez R, Doermer A, et al. Prognostic significance of polo-like kinase (PLK) expression in non-small cell lung cancer. Oncogene. 1997; 14(5): 543–549.
    CrossRefPubMed
  15. Takai N, Miyazaki T, Fujisawa K, et al. Expression of polo-like kinase in ovarian cancer is associated with histological grade and clinical stage. Cancer Lett. 2001; 164(1): 41–49.
    CrossRefPubMed
  16. Macmillan JC, Hudson JW, Bull S, et al. Comparative expression of the mitotic regulators SAK and PLK in colorectal cancer. Ann Surg Oncol. 2001; 8(9): 729–740.
    CrossRefPubMed
  17. Cheng MW, Wang BC, Weng ZQ, et al. Clinicopathological significance of Polo-like kinase 1 (PLK1) expression in human malignant glioma. Acta Histochem. 2012; 114(5): 503–509.
    CrossRefPubMed
  18. Lin P, Wen DY, Dang YW, et al. Comprehensive and Integrative Analysis Reveals the Diagnostic, Clinicopathological and Prognostic Significance of Polo-Like Kinase 1 in Hepatocellular Carcinoma. Cell Physiol Biochem. 2018; 47(3): 925–947.
    CrossRefPubMed
  19. Kneisel L, Strebhardt K, Bernd A, et al. Expression of polo-like kinase (PLK1) in thin melanomas: a novel marker of metastatic disease. J Cutan Pathol. 2002; 29(6): 354–358.
    CrossRefPubMed
  20. Strebhardt, K. Prognostic Value of Pololike Kinase Expression in Melanomas. JAMA: The Journal of the American Medical Association. 2000; 283(4): 479–480.
    CrossRef
  21. Otto T, Sicinski P. Cell cycle proteins as promising targets in cancer therapy. Nat Rev Cancer. 2017; 17(2): 93–115.
    CrossRefPubMed
  22. Bailey FP, Clarke K, Kalirai H, et al. Kinome-wide transcriptional profiling of uveal melanoma reveals new vulnerabilities to targeted therapeutics. Pigment Cell Melanoma Res. 2018; 31(2): 253–266.
    CrossRefPubMed
  23. Grossniklaus HE, Finger PT, Harbour JW, et al. Protocol for the Examination of Specimens From Patients With Uveal Melanoma, https://documents.cap.org/protocols/cp-uveal-melanoma-17protocol-4000.pdf (2017, accessed 12 March 2020).
  24. Remmele W, Stegner HE. [Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue]. Pathologe. 1987; 8(3): 138–140.
    PubMed
  25. R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria, https://www.r-project.org/ (2019, accessed 12 March 2020).
  26. Kassambara A, Kosinski M, Biecek P. survminer: Drawing Survival Curves using ‘ggplot2’. R package version 0.4.6., https://cran.r-project.org/package=survminer (2019, accessed 12 March 2020).
  27. Strebhardt K. Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy. Nat Rev Drug Discov. 2010; 9(8): 643–660.
    CrossRefPubMed
  28. Eckerdt F, Yuan J, Strebhardt K. Polo-like kinases and oncogenesis. Oncogene. 2005; 24(2): 267–276.
    CrossRefPubMed
  29. Takai N, Hamanaka R, Yoshimatsu J, et al. Polo-like kinases (Plks) and cancer. Oncogene. 2005; 24(2): 287–291.
    CrossRefPubMed
  30. Weng Ng WT, Shin JS, Roberts TL, et al. Molecular interactions of polo-like kinase 1 in human cancers. J Clin Pathol. 2016; 69(7): 557–562.
    CrossRefPubMed
  31. Liu XS, Li H, Song B, et al. Polo-like kinase 1 phosphorylation of G2 and S-phase-expressed 1 protein is essential for p53 inactivation during G2 checkpoint recovery. EMBO Rep. 2010; 11(8): 626–632.
    CrossRefPubMed
  32. Yang X, Li H, Zhou Z, et al. Plk1-mediated phosphorylation of Topors regulates p53 stability. J Biol Chem. 2009; 284(28): 18588–18592.
    CrossRefPubMed
  33. Chen J, Dai Gu, Wang YQ, et al. Polo-like kinase 1 regulates mitotic arrest after UV irradiation through dephosphorylation of p53 and inducing p53 degradation. FEBS Lett. 2006; 580(15): 3624–3630.
    CrossRefPubMed
  34. Dias SS, Hogan C, Ochocka AM, et al. Polo-like kinase-1 phosphorylates MDM2 at Ser260 and stimulates MDM2-mediated p53 turnover. FEBS Lett. 2009; 583(22): 3543–3548.
    CrossRefPubMed
  35. Ando K, Ozaki T, Yamamoto H, et al. Polo-like kinase 1 (Plk1) inhibits p53 function by physical interaction and phosphorylation. J Biol Chem. 2004; 279(24): 25549–25561.
    CrossRefPubMed
  36. McKenzie L, King S, Marcar L, et al. p53-dependent repression of polo-like kinase-1 (PLK1). Cell Cycle. 2010; 9(20): 4200–4212.
    CrossRefPubMed
  37. Liu X, Erikson RL. Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells. Proc Natl Acad Sci U S A. 2003; 100(10): 5789–5794.
    CrossRefPubMed
  38. Liu X, Lei M, Erikson RL. Normal cells, but not cancer cells, survive severe Plk1 depletion. Mol Cell Biol. 2006; 26(6): 2093–2108.
    CrossRefPubMed
  39. Guan R, Tapang P, Leverson JD, et al. Small interfering RNA-mediated Polo-like kinase 1 depletion preferentially reduces the survival of p53-defective, oncogenic transformed cells and inhibits tumor growth in animals. Cancer Res. 2005; 65(7): 2698–2704.
    CrossRefPubMed
  40. Ren Y, Bi C, Zhao X, et al. PLK1 stabilizes a MYC-dependent kinase network in aggressive B cell lymphomas. J Clin Invest. 2018; 128(12): 5517–5530.
    CrossRefPubMed
  41. Xiao D, Yue M, Su H, et al. Polo-like Kinase-1 Regulates Myc Stabilization and Activates a Feedforward Circuit Promoting Tumor Cell Survival. Mol Cell. 2016; 64(3): 493–506.
    CrossRefPubMed
  42. Choi BH, Pagano M, Dai W. Plk1 protein phosphorylates phosphatase and tensin homolog (PTEN) and regulates its mitotic activity during the cell cycle. J Biol Chem. 2014; 289(20): 14066–14074.
    CrossRefPubMed
  43. Cárcer Gde. The Mitotic Cancer Target Polo-Like Kinase 1: Oncogene or Tumor Suppressor? Genes. 2019; 10(3): 208.
    CrossRef
  44. Boehringer Ingelheim’s investigational volasertib receives FDA Breakthrough Therapy designation, https://www.boehringer-ingelheim.us/press-release/boehringer-ingelheims-investigational-volasertib-receives-fda-breakthrough-therapy (accessed 1 February 2020).
  45. Volasertib in Combination With Low-dose Cytarabine in Patients Aged 65 Years and Above With Previously Untreated Acute Myeloid Leukaemia, Who Are Ineligible for Intensive Remission Induction Therapy (POLO-AML-2), https://clinicaltrials.gov/ct2/show/NCT01721876?term=polo-aml-2&rank=1 (accessed 1 February 2020).
  46. Van den Bossche J, Lardon F, Deschoolmeester V, et al. Spotlight on Volasertib: Preclinical and Clinical Evaluation of a Promising Plk1 Inhibitor. Med Res Rev. 2016; 36(4): 749–786.
    CrossRefPubMed
  47. Gutteridge RE, Ndiaye MA, Liu X, et al. Plk1 Inhibitors in Cancer Therapy: From Laboratory to Clinics. Mol Cancer Ther. 2016; 15(7): 1427–1435.
    CrossRefPubMed
  48. Lu LY, Yu X. The balance of Polo-like kinase 1 in tumorigenesis. Cell Div. 2009; 4: 4.
    CrossRefPubMed
  49. Lu LY, Wood JL, Minter-Dykhouse K, et al. Polo-like kinase 1 is essential for early embryonic development and tumor suppression. Mol Cell Biol. 2008; 28(22): 6870–6876.
    CrossRefPubMed
  50. Wierer M, Verde G, Pisano P, et al. PLK1 signaling in breast cancer cells cooperates with estrogen receptor-dependent gene transcription. Cell Rep. 2013; 3(6): 2021–2032.
    CrossRefPubMed
  51. de Cárcer G, Venkateswaran SV, Salgueiro L, et al. Plk1 overexpression induces chromosomal instability and suppresses tumor development. Nat Commun. 2018; 9(1): 3012.
    CrossRefPubMed
  52. Raab M, Sanhaji M, Matthess Y, et al. PLK1 has tumor-suppressive potential in APC-truncated colon cancer cells. Nat Commun. 2018; 9(1): 1106.
    CrossRefPubMed
  53. The Cancer Genome Atlas Program, https://www.cancer.gov/about-nci/organization/ccg/research/structural-genomics/tcga (accessed 1 February 2020).
  54. Györffy B, Lanczky A, Eklund AC, et al. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat. 2010; 123(3): 725–731.
    CrossRefPubMed
  55. The Kaplan Meier plotter, www.kmplot.com (accessed 1 February 2020).
  56. Jalili A, Moser A, Pashenkov M, et al. Polo-like kinase 1 is a potential therapeutic target in human melanoma. J Invest Dermatol. 2011; 131(9): 1886–1895.
    CrossRefPubMed
  57. Zhang Z, Zhang G, Gao Z, et al. Comprehensive analysis of differentially expressed genes associated with PLK1 in bladder cancer. BMC Cancer. 2017; 17(1): 861.
    CrossRefPubMed
  58. Chen J, Wu F, Shi Yu, et al. Identification of key candidate genes involved in melanoma metastasis. Mol Med Rep. 2019; 20(2): 903–914.
    CrossRefPubMed
  59. Schmit TL, Zhong W, Setaluri V, et al. Targeted depletion of Polo-like kinase (Plk) 1 through lentiviral shRNA or a small-molecule inhibitor causes mitotic catastrophe and induction of apoptosis in human melanoma cells. J Invest Dermatol. 2009; 129(12): 2843–2853.
    CrossRefPubMed
  60. Posch C, Cholewa BD, Vujic I, et al. Combined Inhibition of MEK and Plk1 Has Synergistic Antitumor Activity in NRAS Mutant Melanoma. J Invest Dermatol. 2015; 135(10): 2475–2483.
    CrossRefPubMed
  61. Chen HY, Villanueva J. Playing Polo-Like Kinase in NRAS-Mutant Melanoma. J Invest Dermatol. 2015; 135(10): 2352–2355.
    CrossRefPubMed
  62. Basile MS, Mazzon E, Fagone P, et al. Immunobiology of Uveal Melanoma: State of the Art and Therapeutic Targets. Front Oncol. 2019; 9: 1145.
    CrossRefPubMed

About cookies

Necessary cookies

Allways active

These cookies are necessary for the proper display and operation of the website. Blocking them may cause the website to malfunction.

Analytical cookies

As part of our website, we use analytical tools, such as Google Analytics, that allow us to verify website traffic. These tools may require the use of cookies.

Community cookies

These are cookies associated with the social networks we use. Accepting them will allow us to associate your visit to the site with our social media profiles.

Marketing cookies

These are cookies responsible for carrying out advertising and marketing activities - consenting to their use will allow us to target you with advertisements based on your previous activities within our website.

Copyright © 2023-2024 Via Medica Regulations Cookie policy Privacy Statement Legal Note